Menu

Trends in Synthetic Biology: Antibody Engineering

The Scientist is bringing together a panel of experts to share their research, discuss current therapeutic approaches, and to offer their insights.

Jan 1, 2018
The Scientist Creative Services Team

Trends in Synthetic Biology: Antibody Engineering from thescientistllc on Vimeo.

As the body’s circulating army of first responders, antibodies recognize and destroy foreign and potentially disease-causing pathogens. The engineering of synthetic antibody forms and conjugates has produced a whole new arsenal of tools for applications in research, diagnostics, and therapeutics. Forward-engineering approaches create new recognition sites and molecular functions for antibody products to accurately and efficiently detect previously undetectable molecular targets with an increased response lifetime. For a closer look at the fastest growing class of synthetic therapeutics, The Scientist is bringing together a panel of experts to share their research, discuss current design and optimization approaches, and to offer insight on the future outlook of antibody engineering. Join us as these experts share best practices and tips for optimally engineered antibodies.

Topics to be covered:

  • Producing more and better antibodies
  • Designing your antibodies for optimal effect

Register Now

Meet the Speakers:

Anne Messer, PhD
Principal Investigator & Professor
Neural Stem Cell Institute
Regenerative Research Foundation
Department of Biomedical Sciences
University at Albany

 

 

Yasmina Abdiche, PhD
CSO
Carterra, Inc.

 

 


 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.